Drugs / PDM608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05950906 | Jun 2023 → Mar 2024 | Parkinson disease | Calibr, a division of Scripps Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDM608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05950906 ↗ |
| Route | Subcutaneous | “Single ascending dose, subcutaneous administration of PDM608” NCT05950906 ↗ |